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Available online 23 May 2017Patients in the latest stages of heart failure are severely compromised, with poor quality of life and frequent hos-
pitalizations. Heart transplantation and left ventricular assist device implantation are viable options only for ami-
nority, and intermittent or continuous infusions of positive inotropes may be needed as a bridge therapy or as a
symptomatic approach. In these settings, levosimendan has potential advantages over conventional inotropes
(catecholamines and phosphodiesterase inhibitors), such as sustained effects after initial infusion, synergy
with beta-blockers, and no increase in oxygen consumption. Levosimendan has been suggested as a treatment
that reduces re-hospitalization and improves quality of life. However, previous clinical studies of intermittent in-
fusions of levosimendan were not powered to show statistical signiﬁcance on key outcome parameters. A panel
of 45 expert clinicians from 12 European countries met in Rome on November 24–25, 2016 to review the litera-
ture and envision an appropriately designed clinical trial addressing these needs. In the earlier FIGHT trial (daily
subcutaneous injection of liraglutide in heart failure patients with reduced ejection fraction) a composite Global
Rank Score was used as primary end-point where death, re-hospitalization, and change in N-terminal-
prohormone-brain natriuretic peptide levelwere considered in a hierarchical order. In the present study,we test-
ed the sameend-point post hoc in the PERSIST and LEVOREP trials on oral and repeated i.v. levosimendan, respec-
tively, and demonstrated superiority of levosimendan treatment vs placebo. The use of the same composite end-
point in a properly powered study on repetitive levosimendan in advanced heart failure is strongly advocated.
© 2017 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Composite end-pointFig. 1. Functional capacity and worsening events during the progression of heart failure
(freely from Cowie MR et al. [5]). A, recovery after ﬁrst episode followed by stable
period of variable length; B, non-surviving the ﬁrst episode; C, poor recovery after ﬁrst
episode followed by deterioration; D, ongoing deterioration with intermittent crises
(advanced heart failure) and unpredictable death point.1. Heart failure, chronic heart failure, and advanced heart failure
Heart failure (HF) is the result of various clinical conditions, all of
which have the common characteristic of reduced myocardial function
either in terms of contractility or in terms of ventricular compliance
and relaxation. Moreover, HF affects not only the heart itself, but may
be considered as a systemic condition in which neurohormonal and in-
ﬂammatory activation mediates cardiac remodeling and disease pro-
gression [1]. The number of patients suffering from chronic HF is
increasing over the years, due several factors, i.e. to advances in medi-
cine and science leading to improved survival from previously life-
threatening scenarios, the high prevalence of serious comorbidities
among the ageing population, and not least the growing life expectancy
itself [2]. HF has become the leading cause of adult hospitalization in the
industrialized world, with an estimated 26 million people suffering
from the disease.
Prognostically effective treatments for HF recommended in the cur-
rent guidelines include inhibitors of the renin–angiotensin–aldosterone
system (comprising angiotensin converting enzyme inhibitors, angio-
tensin receptor blockers, mineralocorticoid receptor antagonists, and
angiotensin-receptor/neprilysin inhibitors), beta-adrenergic blockers,
ivabradine, and devices (either cardiac resynchronization therapy or
implantable cardioverter deﬁbrillators) [3]. These strategies are ﬂanked
by symptomatic treatment, in particular diuretics.
Hospitalization for acute HF is a signiﬁcant predictor of increased
mortality risk, with registries consistently demonstrating high rates of
all-cause 1-year mortality both for acute and chronic HF [4]. Each time
a patient is hospitalized for acute decompensation, there is a risk for a
further worsening of myocardial function, leading to recurring episodes
of hospitalizations for HF (Fig. 1). Moreover, each successive hospitali-
zation carries a higher probability of death [5], and impacts on health
economics, due to the high costs of HF-related hospitalization [4,6,7].
Although strict adherence to the recommended treatment is essen-
tial for favorably shaping both general welfare and outcome of patients
with severe HF, many do not tolerate all of the currently available ther-
apies, due to hypotension or co-morbidities (renal impairment, COPD,
etc.). The advent of CRT represented amilestone in cardiovascularmed-
icine, since it greatly reduced the re-hospitalization rate and mortality
in a relatively large (though necessarily selected) cohort of patients
[8], whereas heart transplantation or left ventricular assist devices
(LVAD) were (and remain) a possibility for only a limited number of
patients.
The later stages of HF are often referred to either as advanced
(AdHF) or end-stage HF. A distinction between the two terms has to
be made, however, according to the criteria established in 2007 by theEuropean Society of Cardiology and endorsed in 2013 by the American
College of Cardiology Foundation/American Heart Association. Both so-
cieties deﬁne AdHF as a condition in which cardiac dysfunction and
symptoms are still potentially reversible, whereas in end-stage HF
they are not [9,10]. AdHF represents a major challenge for both patients
and physicians, as patients experience a severely compromised quality
of life with easily worsening clinical conditions, requiring frequent and
prolonged hospitalizations [11].
Various attempts have been made to identify suitable therapies for
AdHF patients in addition to the ﬁrst-line agents identiﬁed above. The
use of continuous or intermittent infusions of intravenous inotropes
was tested, but concern was raised about increased mortality with
such treatments, notwithstanding favorable hemodynamics and symp-
tomatic improvements in small clinical studies (see Upadya et al. [12]).
Larger trials and meta-analysis appeared to conﬁrm a trend towards
higher mortality risk and did not identify any beneﬁcial impact on hos-
pitalizations [13].
In the early 2000s, a new perspective on the treatment of HF was
opened by the introduction of the inodilator levosimendan, a calcium
sensitizer and potassium channel opener [14]. This drug combines pos-
itive inotropic, vasodilatory, and cardioprotective effects, without in-
creasing oxygen demand. Levosimendan is the most studied inotrope
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advantages of levosimendan in various clinical settings [15–18]. In par-
ticular, the intermittent use of i.v. levosimendan in chronic AdHF has
been suggested to prevent acute decompensation and frequent re-
hospitalization, and possibly to improve other outcomes [15].
2. Aim of the expert consensus meeting
A panel of 45 clinical experts from 12 European countries (Austria,
Denmark, Finland, Germany, Greece, Hungary, Italy, Poland, Slovenia,
Spain, Sweden, and Switzerland) convened in Rome on November
24th–25th, 2016 to (a) review the current data on repetitive
levosimendan studies, (b) proﬁle the patient groups most likely to ben-
eﬁt from repetitive intermittent treatment with i.v. levosimendan,
(c) compare end-points from previous clinical trials in the same set-
tings, and (d) discuss the end-points and the protocol of an adequately
powered trial designed to evaluate efﬁcacy and safety of intermittent i.v.
levosimendan therapy started during the vulnerable phase after a re-
cent hospitalization for HF. This consensus paper presents the conclu-
sions of the expert panel.
3. Levosimendan
Levosimendan is a calcium sensitizer and potassium channel opener
indicated for the treatment of acute HF [14]. Levosimendan has one ac-
tive metabolite, coded OR-1896. Both the parent drug and OR-1896
have similar effects, but levosimendan has a half-life of about 1 h,
whereas OR-1896 reaches its peak plasma concentration 2–3 days
after levosimendan infusion, thus prolonging therapeutic effects beyond
the infusion period [19–22]. The drug was formulated for a 24-hour in-
fusion, after which its pharmacodynamic effects (i.e., increase in cardiac
output and reduction of pulmonary capillary wedge pressure) persist
for at least oneweek [23]. However, some research groups have obtain-
ed interesting resultswith limited duration of the infusion (i.e., 6 to 8 h),
although pharmacokinetic information is limited. Of note, the reduction
in pulmonary vascular resistance after a 6-hour infusion in patientswith
pulmonary hypertension does not seem to persist for 2 weeks as is seen
with the 24-hour infusion [24].
Efﬁcacy and safety of levosimendan have been described in themed-
ical literature. The hemodynamic effects of the drug have been con-
vincingly demonstrated in acute HF patients in two regulatory studies,
i.e. the LIDO [25] and RUSSLAN [26] clinical trials. Moreover, in the reg-
ulatory clinical trial REVIVE [27] levosimendan induced marked relief
from symptoms. Several meta-analyses evaluating approximately
5000 patients of 50 randomized controlled trials demonstrated a reduc-
tion in mortality with levosimendan in different clinical scenarios [28].
Levosimendan also exhibits neurohormonal and anti-inﬂammatory
effects, reducing brain natriuretic peptide (BNP) level, as well as
tumor necrosis factor alfa (TNF-α), interleukin-6 (IL-6), and pro-
apoptotic factors sFas and Fas-ligand levels [29–32]. In addition,
levosimendan improves both right ventricular function [33] and en-
dothelial function, and has a beneﬁcial effect on coronary blood
ﬂow [34,35].
This proﬁle renders intermittent repetitive administration of
levosimendan a potentially valuable treatment option for patients
with AdHF. In fact, levosimendan has several theoretical advantages
over the other commonly used inotropes [14,16], such as the synergy
with beta-blockers and the beneﬁcial effect on renal function and pe-
ripheral organ perfusion.
A panel of international experts recently proposed criteria for the
identiﬁcation of the patients most likely to beneﬁt from repetitive use
of levosimendan in chronic AdHF [36]. Among thosewere patients listed
for heart transplantation or LVAD implantation, as well as patients with
similar clinical proﬁles but not eligible to LVADor transplantation due to
other causes (i.e. mental illness), in whom intermittent repetitive
levosimendan infusions may be viewed as “destination treatment”.4. Clinical studies on the effects of levosimendan in AdHF
Several studies on the repetitive or intermittent administration of
levosimendan in AdHF have already been published and subjected to
meta-analysis [37]. Evidence of clinical beneﬁt was brought forward
[36,37] although data on the subject are heterogeneous both in terms
of methodology and of results: the comparator of levosimendan varied
from placebo to diuretics, or dobutamine; the dosages and interval of
levosimendan administration differed among centers; there was
marked variation in these study design, as the primary and secondary
outcomes.
The safety and efﬁcacy of levosimendan infused every two weeks in
patients refractory to i.v. dobutamine in addition to standard therapy
was tested by the group of Nanas et al. [38] in an open-label comparison
between daily dobutamine plus levosimendan versus daily dobutamine
infusions alone. A total of 36 patients with cardiac decompensation
were enrolled. Half of them were treated with 24-hour infusions of
dobutamine followed by 8-hour infusions for up to three days and
then weekly dobutamine infusions: the other 18 patients received a
24-hour infusion of levosimendan every two weeks in addition to
daily dobutamine. The authors found that levosimendan infusions
were useful to stabilize the majority of patients, and to improve their
clinical and hemodynamic status. Patients' survival improved with this
sequential treatment, whereas higher mortality was reported in the
group treated by dobutamine infusions alone.
Parissis et al. [39] tested the efﬁcacy of ﬁve levosimendan infusions,
administered once every three weeks, in a series of 25 patients with
chronic AdHF. Their patients were randomized 2:1 to levosimendan
and placebo respectively, and all of them underwent echocardiographic
as well as biochemical evaluations before and after each cycle of treat-
ment and at the ﬁnal visit. Left ventricular ejection fraction (LVEF),
N-terminal prohormone of brain natriuretic peptide (NT-proBNP) and
IL-6 levels signiﬁcantly improved after levosimendan therapy.
LVEF was also assessed in a study by Mavrogeni et al. [40], who ad-
ditionally evaluated other echocardiographic parameters such as end-
diastolic and end-systolic volumes and dimensions. All these echocar-
diographic indices were signiﬁcantly improved following monthly
levosimendan infusions for a 6-month-period, and besides, the authors
demonstrated signiﬁcant symptoms improvement and reduction in
mortality with levosimendan, compared to standard care.
Other studies such as those of Papadopoulou et al. [41] and Malfatto
et al. [42] demonstrated improvements in both objective echocardio-
graphic measurements and subjective quality of life measures with
24-h levosimendan. Patients in the Papadopoulou et al. study did not
have a comparator group, whereas Malfatto et al. compared monthly
levosimendan infusions to furosemide, resulting in a signiﬁcant reduc-
tion in New York Heart Association (NYHA) class, and improvements
in echocardiographic parameters and BNP levels. Again, a trend towards
reduction in one-year mortality was seen with levosimendan, although
it did not reach statistical signiﬁcance.
Levosimendan was less effective than prostaglandin E1 in patients
not tolerating the appropriate beta-blocker therapy in the trial by Berger
et al. [43]. In this study, continuous treatment with prostaglandin
E1 was more efﬁcacious than 24-hour levosimendan infusions every
4-weeks in allowing up-titration of beta-blockers. Prostaglandin E1 per-
formed better than levosimendan with regard to the composite end-
point of worsening HF, death, urgent heart transplantation, and/or im-
plantation of LVAD, although mortality did not differ between the two
groups.
Sixty-three patients with decompensated end-stage HF refractory to
standard therapy were randomized by Bonios et al. [44] to receive
levosimendan, dobutamine, or the combination of both drugs. Patients
were ﬁrst treated with inotropes for stabilization, and entered the
study after successful weaning from i.v. inotropic support. Only the
group of patients receiving levosimendan alone showed a signiﬁcant
beneﬁt in event-free survival, whereas the group receiving the
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tality rate favored levosimendan both versus dobutamine alone (19% vs
38%, p = 0.037) and versus the combination group (19% vs 48%, p =
0.009). Similar improvements in the functional capacity of patients re-
ceiving repetitive levosimendan (from 2 to 26 times, with a mean dos-
ing interval of 66.2 ± 12 days) were observed also in another single-
centre, prospective, non-randomized study, by Parle et al. [45].
The largest trial on repetitive administration of inotropes for end-
stage HF [46] in outpatients was the LEVOREP study, a prospective,
multi-centre, randomised, placebo-controlled, double-blind, two-
armed, parallel-group that enrolled 120 patients with chronic stable
HF, in NYHA class III/IV for N3 months, with LVEF ≤35%, and perfor-
mance of b350m at the 6-minutewalk test. The patients were random-
ized to placebo or 6-hour levosimendan infusions every 2weeks for four
times. The combined primary endpoint was improvement in functional
capacity of ≥20% by the 6-minute walk test, plus improvement in pa-
tient quality of life of ≥15% as assessed by the Kansas City Cardiomyop-
athy Questionnaire score (KCCQ). Follow-up lasted 24 weeks, after
which a trend in favour of levosimendan was evident but no signiﬁcant
difference was conﬁrmed. It has been speculated that the primary end-
point was not reached due to under-dosing of the study drug, small
sample size of the study population, and better care of the patients pop-
ulation also in the placebo group as compared to patients not enrolled in
clinical studies, who apparently experience fewer improvements in
functional capacity than the overall study population.
Regarding the secondary endpoint of event-free survival (freedom
from death, heart transplantation/LVAD implantation, or acute HF)
after 24 weeks, ambulatory treatment with levosimendan wasmore ef-
fective than placebo. Across both arms of the study, similar percentages
of patients experienced adverse events.
Recently, intermittent levosimendan has been assessed in two
double-blind, randomized, placebo-controlled trials, the LION-HEART
and LAICA studies [47,48].
LION-HEART [47] was a multi-centre, randomized, double-blind,
parallel group, placebo-controlled trial aiming to test the efﬁcacy
and safety of intravenous administration of repetitive doses of
levosimendan in outpatients with AdHF. Levosimendan was adminis-
tered in an ambulatory setting during a 6-h-period of observation, and
repeated every two weeks. The study lasted 12 weeks (6 cycles of
levosimendan for each patient), after which change in NT-proBNP
from baseline was assessed as the primary endpoint. The reduction in
NT-proBNP was signiﬁcantly in favour of levosimendan, as was
the probability of survival in the Kaplan-Meyer curve at 180 days (all
p b 0.005).
LAICA [48] was an Investigator Initiated Trial evaluating monthly
24-hour infusions of levosimendan for a year in addition to optimal
medical therapy for reducing the incidence of hospitalization for
acute decompensated HF in patients with advanced chronic AdHF. Sec-
ondary endpoints were cumulative incidence of hospitalization for
acute decompensated HF and/or mortality at 30 days, and after 3, 6,
and 12 month; the time-interval from randomization to ﬁrst hospitali-
zation for acute cardiac decompensation or death; incidence of adverse
events; and changes in NYHA functional class over the one-year follow-
up. Ninety-seven patients were randomized: 70 were allocated to
levosimendan and 27 to placebo. Although many patients were lost
to follow-up, statistical analysis was performed considering all 97 pa-
tients enrolled.
LAICA did not demonstrate statistical signiﬁcance for the primary
endpoint, but the results favoured levosimendan both in terms of
fewer admissions for acute decompensated HF and in terms of lower
mortality rates. The rate of adverse events was comparable between
levosimendan and placebo. Ongoing studies are exploring treatment ef-
fects on renal function and cost-effectiveness.
Table 1 summarizes the total doses of levosimendan used in the 10
studies described. Although a trend in favour of the repetitive use of
levosimendan is discernible in the majority of the studies, more robustdata on hospitalization and mortality rates associated with repetitive
use of levosimendan are needed.
5. Primary end-points in AdHF clinical studies
The central clinical aims in the treatment of HF are to relieve symp-
toms, reduce the number and length of hospitalizations and reducemor-
tality. Symptomatic improvement has turned out to be an extremely
elusive endpoint in such trials. There are confounding factors inﬂuencing
its reliable measurement and – although clinically meaningful – symp-
tomsmay not be an ideal primary endpoint to test the efﬁcacy of a treat-
ment. A composite endpoint of mortality and re-hospitalisations would
ensure wide acceptance. However, with this approach only a proportion
of the patients participating in the trial would contribute to the endpoint
unless the follow-up period were extended to years; with a more realis-
tic (i.e. shorter) duration of follow-up, the size of the patient population
would need to bemarkedly higher, and conducting such a study in a rea-
sonable time-frame would be extremely difﬁcult. Having all patient ran-
domized contributing to the endpoint would optimise the needed
sample size and the duration of the study.
Recently, a study with a primary endpoint combining deaths, re-
hospitalizations and positive neurohormonal response (on NT-
proBNP) has been published [49]. In the FIGHT trial (Functional Impact
of GLP-1 for Heart Failure Treatment Study) [49], Margulies et al. set as
primary endpoint a Global Rank Score where each patient is assigned a
numerical value corresponding to their stability index mirroring their
respective clinical conditions.
Each patient is given a score value based on outcome during follow-
up, and then analyzed in hierarchical categories of: (1) time to death;
(2) time to HF hospitalization; and (3) time-averaged proportional
change in NT-proBNP. In this way, deaths are the most important
events, followed by re-hospitalizations and ﬁnally by NT-pro-BNP ele-
vation. This approach was based on the consideration that changes in
NT-proBNP levels over time well represent the severity of HF, and
thus can be a surrogate endpoint for patients not experiencing a clinical
endpoint. This score is easy to interpret: the higher the score value the
more stable the clinical condition. The hierarchical approach increases
the clinical validity of the endpoint, and this new statistical endpoint
has received endorsement by competent regulatory authorities.
In order to compare this newly proposed end-point with the ones
previously used in previous HF trials, we produced post-hoc analyses
of the PERSIST study results on oral levosimendan in chronic heart fail-
ure, and of the LEVOREP study on repetitive levosimendan in AdHF.
The PERSIST study [50] evaluated the effects of oral levosimendan in
patientswith severe chronic HF (NYHA class IIIB-IV). PERSISTwas a ran-
domized, double-blind, placebo-controlled trial of levosimendan 1 mg
once or twice daily versus placebo administered orally for at least
6 months. A total of 307 patients were enrolled. The endpoint of the
study, called “Patient Journey”, was a composite consisting of repeated
symptom assessments, worsening heart failure and mortality up to
60 days. Several repeated assessment of the Minnesota Living with
Heart Failure quality of life (MLHFQoL) score and NT-proBNP levels
were performed. However, a limitation of that study was that, due to
an imperfect randomization, the lower dose of levosimendan was
given to sicker patients. The results of PERSIST were inconclusive with
no statistical difference on the primary endpoint although there was a
numerical sign of mortality risk reduction with levosimendan, and
both QoL and NT-proBNP levels improved.
A simulation performedwith the FIGHT Global Rank Score on the re-
sults of the PERSIST study (Table 2) revealed that this composite param-
eter would have reached statistical signiﬁcance for both the 1 and 2 mg
doses of oral levosimendan (p = 0.0187 and p = 0.0008 respectively).
A similar statistical simulation was performed for the LEVOREP
study [46] (Table 3). Again, signiﬁcant results in favor of levosimendan
were found when the Global Rank Score was used to test the statistical
signiﬁcance of the primary endpoint (p = 0.0239). While this analysis
Table 1
Summary of published trials of repetitive/intermittent levosimendan in advanced heart failure. See text for discussion.
Study name and characteristics Patients
enrolled
Levosimendan dose Infusion
duration
Infusion
frequency
End-points
Efﬁcacy and safety of intermittent, long-term,
concomitant dobutamine and levosimendan
infusions in severe heart failure refractory to
dobutamine alone [38]
36 Bolus of 6 mg/kg followed by 0.2 μg/kg/min
infusion
24-h 2 weeks Survival at 45-days, hemodynamics
Effects of serial levosimendan infusions on left
ventricular performance and plasma biomarkers of
myocardial injury and neurohormonal and immune
activation in patients with advanced heart failure
[39]
25 Bolus of 6 mg/kg followed by 0.1 μg/kg/min
infusion, uptitrated to 0.4 μg/kg/min
24-h 3 weeks LVEF, LV dimensions and volumes,
Nt-proBNP levels, tnt T levels, CRP
levels, IL 6 levels
A 6-month follow-up of intermittent levosimendan
administration effect on systolic function, speciﬁc
activity questionnaire, and arrhythmia in advanced
heart failure [40]
50 Bolus of 6 mg/kg followed by 0.1 μg/kg/min
infusion, uptitration to 0.2 μg/kg/min if tolerated
24-h 30 days Symptoms/QoL, LVEF, LV volumes
and dimensions, mitral
regurgitation, RV systolic pressure
Assessment of quality of life using three different
activity questionnaires in heart failure patients after
monthly, intermittent administration of
levosimendan during a six-month period [41]
20 0.1 μg/kg/min infusion without a loading dose 24-h 30 days QoL anf LVEF
Intermittent levosimendan infusions in advanced
heart failure: favourable effects on left ventricular
function, neurohormonal balance, and one-year
survival [42]
33 Starting 0.1 μg/kg/min, without a loading dose,
uptitration 0.1 μg/kg/min per hour up to
0.4 μg/kg/min
24-h 30 days Hemodynamics and
echocardiographic indices, BNP
Levosimendan and prostaglandin E1 for uptitration of
beta-blockade in patients with refractory, advanced
chronic heart failure [43]
75 Bolus of 12 mg/kg if blood pressure N 95 mm Hg,
followed by 0.1 μg/kg/min infusion, or
continuous infusion without loading dose if
blood pressure b 95 mm Hg
24-h 4 weeks Up-titration of beta-blockers, LVEF,
BNP
Comparison of three different regimens of
intermittent inotrope infusions for end stage heart
failure [44]
63 Either 0.2 μg/kg/min infusion in association with
dobutamine or 0.3 μg/kg/min lone
levosimendan infusion
6-h weekly Hemodynamics, survival/freedom
from LVAD at 3 and 6 months
Efﬁcacy and safety of the pulsed infusions of
levosimendan in outpatients with advanced heart
failure (LevoRep) study: a multicentre randomized
trial [46]
120 0.2 μg/kg/min, without a loading dose 6-h 2 weeks ≥20% improvement in the 6 min
walk test and a ≥ 15% score
increase in the KCCQ; 8-weeks and
24-weeks survival
Multicenter, double-blind, randomized,
placebo-controlled trial evaluating the efﬁcacy and
safety of intermittent levosimendan in outpatients
with advanced chronic heart failure: the LION Heart
Study [47]
69 0.2 μg/kg/min, without a loading dose 6-h 2 weeks NTproBNP changes from baseline,
survival
A randomized, double-blind, placebo controlled
multicenter trial to study efﬁcacy, security, and long
term effects of intermittent repeated levosimendan
administration in patients with advanced heart
failure: LAICA study [48]
97 0.1 μg/kg/min, without a loading dose 24 h 30 days Reduction of AHF hospitalizations,
short and long-term mortality
changes in NYHA functional class
over the one-year
393G. Pölzl et al. / International Journal of Cardiology 243 (2017) 389–395did not change the interpretation of these trials, the results suggest that
Global Rank Score might be an informative endpoint for a study in this
particular patient population with advanced HF.
6. Recommendations
Past experience has shown that evaluation of symptoms as an objec-
tive end-point in HF trials is problematic. Symptoms cannot always be
reliably measured, and may not represent an ideal primary endpoint
to test the efﬁcacy of a treatment. A composite endpoint combining
death and re-hospitalizations would enjoy widespread acceptance, al-
though it presents two interrelated drawbacks: follow-up needs to be
long enough to enable a relevant number of patients to reach theTable 2
PERSIST [50] result with the FIGHT [49] endpoint. Signiﬁcant result in favor of intermittent
levosimendan in the Global Rank Score.
Global Rank Scorea p-Valueb
Levosimendan 1 mg (n = 102) 159 (95) 0.0187
Levosimendan 2 mg (n = 103) 173 (90) 0.0008
Levosimendan 1or 2 mg (n = 205) 166 (93) 0.0009
Placebo (n = 102) 130 (75)
a Mean (SD).
b Wilcoxon-Mann-Whitney Test.endpoint, and the sample size has to be adequately large in order to as-
certain statistical power, which in turn extends the period of recruit-
ment to an extent that may itself be infeasible.
We hypothesized that, compared to placebo, repetitive administra-
tion of levosimendan early in the period after discharge from an acute
episode of worsening HF may be associated with greater clinical stabil-
ity through 14 weeks, especially if assessed with the composite clinical
end-point consisting of mortality, acute HF episodes and change in na-
triuretic peptide levels evaluated in hierarchical manner by Margulies
et al. [49].
As secondary endpoints we suggest to consider all the individual
components of the Global Rank Score at 14weeks, changes in functional
status (measured by NYHA class and 6-minute walking test at baseline
and 14weeks), symptoms (evaluatedwithKansas City CardiomyopathyTable 3
LEVOREP [46] result with the FIGHT [49] endpoint. Signiﬁcant result in favor of intermit-
tent levosimendan in the Global Rank Score.
Global Rank Scorea p-Valueb
Levosimendan (n = 63) 67 (36) 0.0239
Placebo (n = 57) 53 (32)
a Mean (SD).
b Wilcoxon-Mann-Whitney Test.
394 G. Pölzl et al. / International Journal of Cardiology 243 (2017) 389–395Questionnaire from baseline to 14 weeks), combined events and cumu-
lative numbers of events/hospital admissions/days alive out of hospital.
With the Global Rank Score as primary endpoint of a trial, every pa-
tient would contribute to the endpoint through one ormore of the hier-
archical categories: either if he/she experiences death or an episode of
worsening HF or a change in NT-proBNP measurement. This approach
would create an opportunity to recruit an advanced but fairly stable
HF population that would be comparatively easy to enroll and should
have a low rate of drop-out by virtue of the shorter treatment time
per patient.
7. Conclusion
Although only a limited proportion of all HF patients belong to the
sub-group of chronic AdHF, this population exerts a huge impact both
in terms of health care resources and costs and in terms of emotional in-
volvement for physicians and relatives. Despite being treated with all
recommended evidence-based medications, these patients may experi-
ence clinical deterioration, need for re-hospitalization and further de-
cline in the trajectory of their HF.
It appears that repetitive levosimendan may help patients to
gain a longer stability period and a better QoL and postpone re-
hospitalizations, easing the challenge of treating their failing heart. In-
termittent use of levosimendan has been evaluated in 10 trials with a
multitude of chronic AdHF patients treated with this approach (see
Table 1). Differences among the various trials make it difﬁcult to raise
univocal and ﬁrm conclusion; nonetheless, repetitive infusions of
levosimendanhave demonstrated several beneﬁts in terms of improved
hemodynamics, symptoms, re-hospitalization rates, and biomarkers.
The panel recommends initiating an adequately powered clinical
trial that utilizes as primary-end point a composite such the one used
for the FIGHT trial on liraglutide [49]. Cardiac mortality and re-
hospitalization are advocated as secondary end-points.
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